Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
15 June 2018Website:
http://www.verrica.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 22:07:54 GMTDividend
Analysts recommendations
Institutional Ownership
VRCA Latest News
SAN FRANCISCO , Oct. 30, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Verrica Pharmaceuticals Inc. investors that the firm is investigating potential legal claims relating to the company's unsuccessful efforts in 2021 and 2022 to secure regulatory approval for its drug product VP-102, designed to treat molluscum. Current shareholders are encouraged to contact the firm.
- Posters to highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by histological clearance -
- Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure - Sales and marketing efforts to focus on pediatricians and expand access beyond dermatologists WEST CHESTER, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced a restructuring of its sales and operating teams to reduce costs and expand access to YCANTH ® for the treatment of molluscum contagiosum.
NEW ORLEANS , Sept. 27, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.
Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.21 per share a year ago.
- Reports YCANTH ® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH's distribution footprint to include Cencora, Inc. as a specialty distributor –
VP-315 was well tolerated with no reported treatment-related serious adverse events All patients treated with VP-315 had a reduction in tumor size with an overall reduction in tumor size of all lesions treated in Part 2 of approximately 86% Approximately 51% of lesions treated in Part 2 achieved complete histological clearance Patients with residual tumor on average achieved an approximate 71% reduction in tumor size ~3.6 million basal cell carcinomas diagnosed in the U.S. each year, which is expected to continue to grow due to aging US population, better diagnosis and increased exposure to risk factors WEST CHESTER, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced preliminary positive results from Part 2 of its Phase 2 clinical trial studying VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma.
WEST CHESTER, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 14, 2024, to discuss the Company's financial results for the second quarter ended June 30, 2024, and provide an overview of topline results from Part 2 of the Phase 2 trial of VP-315 for the treatment of basal cell carcinoma.
- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and is clinically proven to be safe and effective WEST CHESTER, Pa., July 01, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
Verrica Pharmaceuticals Inc. (VRCA) reported a quarterly loss of $0.38 per share, which was better than the Zacks Consensus Estimate of a loss of $0.54 per share. This is compared to a loss of $0.13 per share in the same quarter last year.
What type of business is Verrica Pharmaceuticals?
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
What sector is Verrica Pharmaceuticals in?
Verrica Pharmaceuticals is in the Healthcare sector
What industry is Verrica Pharmaceuticals in?
Verrica Pharmaceuticals is in the Biotechnology industry
What country is Verrica Pharmaceuticals from?
Verrica Pharmaceuticals is headquartered in United States
When did Verrica Pharmaceuticals go public?
Verrica Pharmaceuticals initial public offering (IPO) was on 15 June 2018
What is Verrica Pharmaceuticals website?
https://www.verrica.com
Is Verrica Pharmaceuticals in the S&P 500?
No, Verrica Pharmaceuticals is not included in the S&P 500 index
Is Verrica Pharmaceuticals in the NASDAQ 100?
No, Verrica Pharmaceuticals is not included in the NASDAQ 100 index
Is Verrica Pharmaceuticals in the Dow Jones?
No, Verrica Pharmaceuticals is not included in the Dow Jones index
When was Verrica Pharmaceuticals the previous earnings report?
No data
When does Verrica Pharmaceuticals earnings report?
The next expected earnings date for Verrica Pharmaceuticals is 08 November 2024